Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults

[1]  P. Klenerman,et al.  Humoral and cellular immunity to RSV in infants, children and adults. , 2018, Vaccine.

[2]  H. Schuitemaker,et al.  Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. , 2016, JAMA.

[3]  S. Johnston,et al.  RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection , 2015, Nature Communications.

[4]  Andrew J. Pollard,et al.  Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults , 2015, Science Translational Medicine.

[5]  A. Giuliani,et al.  Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections , 2015, Science Translational Medicine.

[6]  A. Folgori,et al.  Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates , 2015, Molecular therapy. Methods & clinical development.

[7]  J. Wrammert,et al.  Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. , 2015, American journal of respiratory and critical care medicine.

[8]  A. Falsey,et al.  Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem , 2015, Drugs & Aging.

[9]  Mark M. Davis,et al.  A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory , 2014, Science Translational Medicine.

[10]  David Baker,et al.  Proof of principle for epitope-focused vaccine design , 2014, Nature.

[11]  E. Walsh,et al.  Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Factors Determining Progression to Lower Respiratory Tract Disease , 2013, The Journal of infectious diseases.

[12]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[13]  D. Hui,et al.  High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Hamid,et al.  A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity , 2013, Science Translational Medicine.

[15]  A. Bentley,et al.  A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom , 2013, Health Economics Review.

[16]  A. Falsey,et al.  AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. , 2013, The Lancet. Infectious diseases.

[17]  U. Baxa,et al.  Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.

[18]  A. Folgori,et al.  Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials , 2013, Expert review of vaccines.

[19]  R. Cortese,et al.  Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus , 2013, PloS one.

[20]  M. Esser,et al.  Adults 65 Years Old and Older Have Reduced Numbers of Functional Memory T Cells to Respiratory Syncytial Virus Fusion Protein , 2012, Clinical and Vaccine Immunology.

[21]  Daniel E. Zak,et al.  Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity , 2012, Proceedings of the National Academy of Sciences.

[22]  K. Ladell,et al.  A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years , 2012, PloS one.

[23]  M. Kretzschmar,et al.  Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. , 2012, The Journal of infectious diseases.

[24]  E. Walsh,et al.  Respiratory Syncytial Virus Infection in Elderly Adults , 2012, Drugs & aging.

[25]  S. Buchbinder,et al.  Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). , 2012, The Journal of infectious diseases.

[26]  K. Edwards,et al.  Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. , 2012, The Journal of infectious diseases.

[27]  Hong Zhou,et al.  Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  C. Palomo,et al.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention , 2012, Proceedings of the National Academy of Sciences.

[29]  P. Piedra,et al.  Role of Neutralizing Antibodies in Adults With Community-Acquired Pneumonia by Respiratory Syncytial Virus , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  D. Barouch,et al.  Adenovirus Serotype 5-Specific Neutralizing Antibodies Target Multiple Hexon Hypervariable Regions , 2011, Journal of Virology.

[31]  E. Walsh,et al.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults. , 2010, The Journal of infectious diseases.

[32]  P. Correale,et al.  Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects , 2010, Immunity & Ageing.

[33]  Cedrik M. Britten,et al.  Response definition criteria for ELISPOT assays revisited , 2010, Cancer Immunology, Immunotherapy.

[34]  R. Cortese,et al.  Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses , 2009, Infection and Immunity.

[35]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[36]  Harry B. Greenberg,et al.  Comparison of the Influenza Virus-Specific Effector and Memory B-Cell Responses to Immunization of Children and Adults with Live Attenuated or Inactivated Influenza Virus Vaccines , 2006, Journal of Virology.

[37]  K. Marsh,et al.  Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. , 2006, Vaccine.

[38]  E. Walsh,et al.  Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[39]  R. V. van Lier,et al.  Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung , 2005, The Journal of experimental medicine.

[40]  B. Walker,et al.  Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1 , 2005, The Journal of Immunology.

[41]  R. V. van Lier,et al.  Respiratory syncytial virus-specific CD8+ memory T cell responses in elderly persons. , 2005, The Journal of infectious diseases.

[42]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[43]  H. McShane,et al.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans , 2004, Nature Medicine.

[44]  E. Walsh,et al.  Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. , 2004, The Journal of infectious diseases.

[45]  P. S. Bennett,et al.  Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. , 2004, Human gene therapy.

[46]  Derick R. Peterson,et al.  Risk factors for severe respiratory syncytial virus infection in elderly persons. , 2004, The Journal of infectious diseases.

[47]  K.,et al.  Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. , 2003, The Journal of pediatrics.

[48]  R. Dittus,et al.  Influenza– and Respiratory Syncytial Virus–Associated Morbidity and Mortality in the Nursing Home Population , 2003, Journal of the American Geriatrics Society.

[49]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[50]  A. Osterhaus,et al.  Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. , 2002, Vaccine.

[51]  E. Walsh,et al.  Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults , 1999, Journal of medical virology.

[52]  E. Walsh,et al.  Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. , 1998, The Journal of infectious diseases.

[53]  A. Falsey,et al.  Respiratory syncytial virus and influenza A infections in the hospitalized elderly. , 1995, The Journal of infectious diseases.

[54]  A. Falsey,et al.  Acute Respiratory Tract Infection in Daycare Centers for Older Persons , 1995, Journal of the American Geriatrics Society.

[55]  D. Fulton,et al.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children , 1994 .

[56]  C. Hall,et al.  Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children , 1993 .

[57]  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. , 1998, Pediatrics.